Generic Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Allergan

Tuesday, October 10, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 10, 2017 /PRNewswire/ --

If you want a Stock Review on CPRX, FLXN, SUPN, or AGN then come over

to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com revisits the Generic Drugs industry, focusing on the performance of Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Flexion Therapeutics Inc.
(NASDAQ: FLXN), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), and Allergan PLC (NYSE: AGN). According to an article on Pharmaceutical Online, growth opportunities for generic medicines remain strong and positive. The availability of cost-effective and safe generic alternatives offers a tool that can be used to balance access to and affordability of many major therapies required to maintain a healthy population of patients across multiple disease areas. These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at: http://dailystocktracker.com/register/

Catalyst Pharmaceuticals 

Coral Gables, Florida-based Catalyst Pharmaceuticals Inc.'s stock finished Monday's session 3.61% lower at $2.67 with a total trading volume of 419,075 shares. Over the last month and since the start of this year, the Company's shares have advanced 2.30% and 154.29%, respectively. The stock is trading above its 200-day moving average by 32.11%. Moreover, shares of Catalyst Pharma, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have a Relative Strength Index (RSI) of 54.34. Your complete research report on CPRX can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=CPRX

Flexion Therapeutics 

Shares in Burlington, Massachusetts headquartered Flexion Therapeutics Inc. dropped 5.65%, ending yesterday's session at $28.24. A total volume of 8.73 million shares was traded, which was above their three months average volume of 674,640 shares. The stock has gained 18.86% in the past month, 27.44% in the previous three months, and 48.48% on an YTD basis. The Company's shares are trading 17.67% above their 50-day moving average and 30.41% above their 200-day moving average. Moreover, shares of Flexion Therapeutics, which focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, have an RSI of 63.14.

On October 06th, 2017, Flexion Therapeutics announced that the US FDA approved Zilretta™ (triamcinolone acetonide extended-release injectable suspension) - the first and only extended-release, intra-articular injection for osteoarthritis knee pain. Zilretta is a non-opioid medicine that employs the Company's proprietary microsphere technology to provide proven pain relief over 12 weeks.

On October 09th, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $36 a share to $42 a share. A free report on FLXN is just a click away at: http://dailystocktracker.com/registration/?symbol=FLXN

Supernus Pharma 

On Monday, Rockville, Maryland-based Supernus Pharmaceuticals Inc.'s stock saw a decline of 2.95%, to close the day at $41.15. A total volume of 437,870 shares was traded. The Company's shares have advanced 62.97% on an YTD basis. The stock is trading 17.32% above its 200-day moving average. Additionally, shares of Supernus Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, have an RSI of 47.59.  

On September 18th, 2017, Supernus Pharma announced the outcome of the planned interim analysis from the first Phase-III clinical trial on SPN-810. Based on the predefined criteria for dropping a dose arm, the lower dose of 18 mg will be eliminated. Moving forward, all patients will be randomized to either the 36-mg dose arm or placebo until the predetermined total number of patients are enrolled without changing the size of the trials.

On September 19th, 2017, research firm Stifel downgraded the Company's stock rating from 'Buy' to 'Hold', with a target price of $47 per share. Sign up for your complimentary research report on SUPN at: http://dailystocktracker.com/registration/?symbol=SUPN

Allergan 

Shares in Dublin, Ireland headquartered Allergan PLC ended the day 1.84% lower at $202.94. A total volume of 2.50 million shares was traded, which was above their three months average volume of 2.24 million shares. The stock is trading below its 50-day moving average by 9.79%. Furthermore, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have an RSI of 34.37.  

On September 26th, 2017, Allergan announced that ACZONE® (dapsone) Gel, 7.5%, a prescription medicine used on the skin to treat acne in people 12 years and older, has received a Teen Vogue Acne Award for "Best Prescription Product." This is the first year that Teen Vogue, a publication regarded as an information destination for the next generation, has honored acne-fighting products on the market with its own dedicated awards.

On October 02nd, 2017, research firm Barclays reiterated its 'Equal Weight' rating on the Company's stock. Register for free on DailyStockTracker.com and download the latest research report on AGN at: http://dailystocktracker.com/registration/?symbol=AGN

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store